ReviewFrontiers in aging neuroscience2016
Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease.
Review in Frontiers in aging neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Modeling of Fiber Orientation-Dependent R1 Relaxation in Human White Matter In Vivo Within The Framework of The Transient Hydrogen Bond Model.Magnetic resonance in medicine · 2026Article
- Comparative Analysis of Deep Learning Techniques in Alzheimer's Disease Diagnosis: Trends, Challenges, and Future Directions.MethodsX · 2026Review
- Research trends of piezoelectric materials in neurodegenerative disease applications.Bioactive materials · 2025Review
- Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Neural Network in the Analysis of the MR Signal as an Image Segmentation Tool for the Determination of TInternational journal of molecular sciences · 2023Article
- Exploring the potential of mindfulness-based therapy in the prevention and treatment of neurodegenerative diseases based on molecular mechanism studies.Frontiers in neuroscience · 2023Review
- Apolipoprotein ε4 modifies obesity-related atrophy in the hippocampal formation of cognitively healthy adults.Neurobiology of aging · 2022Article
- AD Resemblance Atrophy Index of Brain Magnetic Resonance Imaging in Predicting the Progression of Mild Cognitive Impairment Carrying Apolipoprotein E-ε4 Allele.Frontiers in aging neuroscience · 2022Article
- Dementia and Major Neurocognitive Disorders: Some Lessons Learned One Century after the first Alois Alzheimer's Clinical Notes.Geriatrics (Basel, Switzerland) · 2021Article
- Systems modeling of white matter microstructural abnormalities in Alzheimer's disease.NeuroImage. Clinical · 2020Article
- Near-infrared Fluorescence Ocular Imaging (NIRFOI) of Alzheimer's Disease.Molecular imaging and biology · 2019Article
- T2 Relaxometry and Diffusion Tensor Indices of the Hippocampus and Entorhinal Cortex Improve Sensitivity and Specificity of MRI to Detect Amnestic Mild Cognitive Impairment and Alzheimer's Disease Dementia.Journal of magnetic resonance imaging : JMRI · 2019Article
- Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review.Nanomaterials (Basel, Switzerland) · 2018Review
- Altered Macular Microvasculature in Mild Cognitive Impairment and Alzheimer Disease.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2018Article
- Review
- Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease.Alzheimer's research & therapy · 2018Article
- Article
- A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults.Clinical interventions in aging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent pharmaceutical trials have demonstrated that slowing or reversing pathology in Alzheimer's disease is likely to be possible only in the earliest stages of disease, perhaps even before significant symptoms develop. Pathology in Alzheimer's disease accumulates for well over a decade before symptoms are detected giving a large potential window of opportunity for intervention. It is therefore important that imaging techniques detect subtle changes in brain tissue before significant macroscopic brain atrophy. Current diagnostic techniques often do not permit early diagnosis or are too expensive for routine clinical use. Magnetic Resonance Imaging (MRI) is the most versatile, affordable, and powerful imaging modality currently available, being able to deliver detailed analyses of anatomy, tissue volumes, and tissue state. In this mini-review, we consider how MRI might detect patients at risk of future dementia in the early stages of pathological change when symptoms are mild. We consider the contributions made by the various modalities of MRI (structural, diffusion, perfusion, relaxometry) in identifying not just atrophy (a late-stage AD symptom) but more subtle changes reflective of early dementia pathology. The sensitivity of MRI not just to gross anatomy but to the underlying "health" at the cellular (and even molecular) scales, makes it very well suited to this task.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.